Turn Therapeutics Inc.
TTRXTurn Therapeutics is a clinical-stage biopharmaceutical company developing non-systemic, non-biologic topical immunomodulators for inflammatory skin diseases and fungal infections.
Earnings
Next report
Sep 2, 2026 (in 2 months)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Turn Therapeutics is a clinical-stage biopharmaceutical company developing non-systemic, non-biologic topical immunomodulators for inflammatory skin diseases and fungal infections. The company leverages its proprietary PermaFusion delivery platform to create treatments that inhibit pro-inflammatory cytokines without systemic absorption or the use of steroids. Its primary focus is advancing its lead candidate, GX-03, through clinical trials for moderate-to-severe eczema and onychomycosis.
Turn Therapeutics differentiates itself by offering non-steroidal, non-biologic topical alternatives that achieve immunomodulation without systemic side effects or injection burden.
Questions, answered.
- What is Turn Therapeutics Inc.'s market cap?
- Turn Therapeutics Inc. (TTRX) has a market capitalization of $262.4M and trades on NASDAQ.
- Who are Turn Therapeutics Inc.'s competitors?
- Turn Therapeutics Inc.'s key competitors include Sanofi, Regeneron Pharmaceuticals, Bausch Health, and others. These companies compete in similar markets and product categories.
- Who does Turn Therapeutics Inc. partner with?
- Turn Therapeutics Inc.'s notable partners include Medline, MiMedx, McKesson, and others.
- Where is Turn Therapeutics Inc. headquartered?
- Turn Therapeutics Inc. is headquartered in United States of America. It has been publicly traded since 2025.